Showing 2551-2560 of 8819 results for "".
SkinTyte Face & Neck Treatment
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/skintyte-face-neck-treatment/19483/Dr. Catherine Fisher performs the SkinTyte Constant Motion Technique to the face and neck of a patient.Nonsurgical Skin Tightening and Facelifts
https://practicaldermatology.com/series/c-suite-chats/nonsurgical-skin-tightening-and-facelifts/54266/Kim Laudati, founder and president of SomaCell, discusses recent demand for minimally invasive, natural-looking treatments and how her company's nonsurgical skin tightening and facelifts help address that trend.DWTV Extra: Skin and Scalp Health
https://practicaldermatology.com/series/dermwire-tv/dwtv-extra-skin-and-scalp-health/54147/Chesahna Kindred, MD, MBA, FAAD, discusses an event at the Science of Skin & Scalp Studio in New York, New York, featuring interactive rooms led by dermatologists, beauty experts, and influencers living with chronic inflammatory conditions sharing stories and shaping the conversation around skinDermwire TV: 2025 in Review
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-2025-in-review/54093/Dermwire TV takes a look back at the most popular stories from the Practical Dermatology news and multimedia ecosystem.IL-31’s Role in Prurigo Nodularis
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/il-31s-role-in-prurigo-nodularis/48804/Raj Chovatiya, MD, PhD, MSCI, FAAD, explains the role of the IL-31 pathway in neuroinflammatory disease such as prurigo nodularis.Effector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/48960/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urEffector Cell Response Inhibitors
https://practicaldermatology.com/series/c-suite-chats/effector-cell-response-inhibitors/48959/Excellergy cofounder Alexander Eggel, PhD, and CEO Todd Zavodnick discuss a recent Journal of Allergy and Clinical Immunology article validating the trifunctional mechanism of action of effector cell response inhibitors (ECRIs) for the treatment of allergic diseases, including chronic spontaneous urSpecial Considerations for Biologic Therapies in Pediatric and Adult Patients with Atopic Dermatitis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37173/Elizabeth Lippner, MD, MA, Attending Physician in the Division of Allergy and Immunology and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine, lists some of the most important considerations when prescribing biologic therapies for atopic dermatitis patients ofNew Devices and Adaptogens
https://practicaldermatology.com/conferences/science-of-skin-summit-2025/tbd/39741/Jacqueline Watchmaker, MD, explores the intersection of medical devices and adaptogenic therapies in skincare. This video was recorded at the Science of Skin Summit in Austin, TX.Welcome to the Dermatology Hub: Neuroimmune Network
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/welcome-to-the-dermatology-hub-neuroimmune-network/39772/Practical Dermatology chief medical editor Neal Bhatia, MD, FAAD, explains what clinicians can expect from the Dermatology Hub: Neuroimmune Network, a unique editorial platform that will be updated monthly with exciting new content.